相关实验视频

Updated: Jun 24, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

背后的机制在获得的抗博特佐米布的非小细胞肺癌细胞中逆转了TRAIL敏感性

Leonie De Wilt^1,2, Bartosz Kamil Sobocki^3,2, Gerrit Jansen⁴

¹Department of Medical Oncology, Amsterdam University Medical Centers, Location VUMC, Vrije Universiteit Amsterdam, Amsterdam 1007MB, the Netherlands.

Cancer drug resistance (Alhambra, Calif.)

|June 5, 2024

概括

耐博特佐米布的非小细胞肺癌细胞对与瘤亡因子 (TNF) 相关的亡诱导性联结体 (TRAIL) 疗法产生敏感性. 这种增强的敏感性涉及外部和内在的亡途径,特别是 TRAIL-R1 转移到脂质中.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症治疗癌症治疗

背景情况:

向与瘤亡因子 (TNF) 相关的诱导亡联体 (TRAIL) 死亡受体是癌症治疗的一种策略,包括非小细胞肺癌 (NSCLC).
在基于 TRAIL 的癌症治疗中,亡耐药性仍然是一个重大挑战.

研究的目的:

调查对抗博特佐米布 (BTZ) 耐药NSCLC变体中TRAIL敏感性背后的亡机制.
探索TRAIL敏感NSCLC中内在和外在亡途径的联合诱导.

主要方法:

在BTZ抗性NSCLC变体中使用MTT和克隆基因分析评估TRAIL敏感性.
利用RT-qPCR,ELISA和西部涂抹来分析亡途径中的基因和蛋白质表达.
采用流式细胞计量用于细胞亡和细胞因子分析,以及siRNA用于基因沉默.

主要成果:

抗BTZ的A549细胞 (A549BTZR) 显示出TRAIL敏感性,与父细胞A549细胞不同.
在A549BTZR细胞中,TNFRSF11B (骨质保护素) 和caspases的mRNA表达增加,以及OPG,IL-6和IL-8蛋白水平升高.
将 TRAIL-R1 转移到脂质中增强了 TRAIL 诱导的亡,同时在内在途径中观察到增加了 Mcl-1 和 Bcl-2,减少了 Bcl-xL.

结论:

在A549BTZR细胞中增加的TRAIL-R1敏感性与其重新定位到脂质中有关.
外在和内在的亡途径都受到上调,这有助于对BTZ耐药NSCLC的TRAIL敏感性.
了解这些机制可以为NSCLC提供新的治疗策略.

关键词:

在Bcl-2家族中.轨道的轨道是一个轨道.博尔特佐米布 (Bortezomib) 是一种药物.细胞因子细胞因子脂质漂浮艇是什么意思脂质漂浮艇是什么意思电阻的阻力可以敏感化敏感化

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...